APA (7th ed.) Citation

Westphal, D., Garzarolli, M., Sergon, M., Horak, P., Hutter, B., Becker, J., . . . Surowy, H. (2021). High tumour mutational burden and EGFR/MAPK pathway activation are therapeutic targets in metastatic porocarcinoma*. British Journal of Dermatology, 185(6), 1186. https://doi.org/10.1111/bjd.20604

Chicago Style (17th ed.) Citation

Westphal, D., et al. "High Tumour Mutational Burden and EGFR/MAPK Pathway Activation Are Therapeutic Targets in Metastatic Porocarcinoma*." British Journal of Dermatology 185, no. 6 (2021): 1186. https://doi.org/10.1111/bjd.20604.

MLA (9th ed.) Citation

Westphal, D., et al. "High Tumour Mutational Burden and EGFR/MAPK Pathway Activation Are Therapeutic Targets in Metastatic Porocarcinoma*." British Journal of Dermatology, vol. 185, no. 6, 2021, p. 1186, https://doi.org/10.1111/bjd.20604.